Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04075604 · ClinicalTrials.gov registry record · Phase 2
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT04075604 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 23 participants.
The verdict
NCT04075604, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer
Interventions
- DRUG Anastrozole
- DRUG Palbociclib
- BIOLOGICAL Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-10-18 |
| Est. Completion | 2021-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04075604
The ClinicalTrials.gov registry entry for NCT04075604 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Anastrozole is the first listed.
NCT04075604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04075604 about?
NCT04075604 is a clinical study titled "A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer". A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer
What is the current status of trial NCT04075604?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2019-10-18. Estimated completion is 2021-07-27.
What interventions are being tested in trial NCT04075604?
The interventions under investigation include: Anastrozole (DRUG), Palbociclib (DRUG), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04075604?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.